The involvement of mesalazine concentration in colonic mucosa of patients with ulcerative colitis under treatment with oral mesalazine

The involvement of mesalazine concentration in colonic mucosa of patients with ulcerative colitis under treatment with oral mesalazine - The involvement of mesalazine concentration in colonic mucosa of UC patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011455

Enrollment

Registered

2013-09-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

Asacol group Pentasa Group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1:Patients with UC 2:Patients with actice UC (score of UC-DAI:3-8) 3:Patients treated with pentasa (=/<2250mg) 4:An outpatient

Exclusion criteria

Exclusion criteria: 1:UC patients who were treated with pentasa enema or salazosulfapyridine suppository 2:Patients with rectal sparing 3:Patients who have a contraindication against mesalazine 4:Patients with severe renal failure 5:Patients with severe hepatic failure 6:Patients treated with prokinetic agents 7:Concomitant malignancies 8:Patients after gastrectomy 9:Under 20 year-old 10:no agreement for this study

Design outcomes

Primary

Measure	Time frame
concentration measurement of colinic mesalazine	—

Secondary

Measure	Time frame
1:Clinical activity index (partial UC-DAI) 2:Endoscopic findings 3:Safety	—

Countries

Japan

Contacts

Public ContactTakuya Yoshino

Kyoto University Hospital Department of Gastroenterology and Hepatology

075-751-4319

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026